Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data
Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models
Biopticon today released the latest version of their TumorManagerTM Program (version 1.3). It will be shown along with the TumorImagerTM at the American Association of Cancer Research (AACR) Exhibition in Chicago, IL in early April. This is the first major upgrade to the TumorManagerTM and incorporates many user requested enhancements making it the most flexible, powerful and easy to use pre-clinical oncology study management program available today.
“We are pleased to be able to quickly incorporate so many of our current users’ requested enhancements” said Jim Patterson, Biopticon’s Vice President of Sales and Marketing. “This new release greatly expands the program’s flexibility by allowing the user to import data from other types of preclinical studies (e.g. fluorescence imaging systems). Randomizations can also be performed on imported external data as well as tumor volume, animal weight etc. Finally, our users have repeatedly told us TumorImagerTM is exceptionally intuitive to learn and easy to use program and the addition of the Automatic Measurement Status function makes it even easier for users to know at a glance that they have completed measurements on all scheduled animals. We believe that our Tumor Management System is becoming the gold standard for simplifying, automating and improving data quality in preclinical oncology studies.”
Dr. Cem Girit, Founder and President, added “we greatly appreciate the ongoing feedback and innovative suggestions from our users and look forward to implementing many more of their ideas in future versions.”